SHELTON, CONNECTICUT -- June 9, 2016 -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a pioneer in developing nanomedicines that directly attack viruses using biomimicry, announced today that it will present at the LDMicro Invitational Conference in Los Angeles, CA on June 9, 2016.
The presentation by Eugene Seymour, MD, MPH, CEO is scheduled to begin at 10am Pacific Daylight Time and will report recent progress as well as explain the nature of the NanoViricides technology.
NanoViricides is actively developing topical antivirals against several different herpesvirus indications, namely, cold sores caused by HSV-1, genital ulcers caused by HSV-2, shingles caused by VZV (the chickenpox virus), and ocular herpes keratitis. The total market size for these indications is estimated to be several billions of dollars. The Company has previously shown complete survival in lethally infected animals with HSV-1 H129 strain infection. The H129 strain is derived from a clinical strain and is a highly infectious, neurotropic virus that causes very high morbidity. Since then the Company has been engaged in further drug optimization and process engineering developments necessary for performing manufacture under current Good Manufacturing Practices (cGMP). A cGMP product is needed for human clinical trials in the USA.
NanoViricides is one of very few small bio-pharma companies that possess their own pilot scale cGMP manufacturing facilities. NanoViricides believes this internal manufacturing capability helps in rapid progress to clinical trials for all of our novel, industry-leading nanomedicine drug candidates. Internal manufacturing also maximally protects our intellectual property. In addition, our multi-kilogram batch production capacity may allow market entry as a stand-alone pharmaceutical company while enabling early revenues, once a product is licensed.
NanoViricides is also working on developing a broad-spectrum nanoviricide to treat diseases caused by several flaviviruses. These flaviviruses include all four subtypes of dengue viruses, as well as the recent epidemic Zika virus, among others. There are no assurances that this work will lead to an effective drug in a rapid timeframe.
NanoViricides is also developing two broad-spectrum drugs to treat influenza virus infections, namely, Injectable FluCide™ for the treatment of severely ill, hospitalized patients, and Oral FluCide™ for the treatment of our-patients.
The presentation will be available on the Company website at http://www.nanoviricides.com/investorinfo.html.
About NanoViricidesFDA refers to US Food and Drug Administration. EMA refers to the European Union’s office of European Medical Agency.